Interestingly, a report on the effects of dapagliflozin discontinuation after label withdrawal for T1D has documented a substantial deterioration of glucose, weight control and insulin doses after 3–6 months [28]. The gene discussed is INS; the disease is type 1 diabetes mellitus.